Eloxx Pharmaceuticals, Inc.

4.11 USD
+3.41 (+487.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Eloxx Pharmaceuticals, Inc. stock is up 356.67% since 30 days ago. The next earnings date is Jun 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.46% of the previous 25 June’s closed higher than May.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.